EIB signs EUR 20 mil. venture debt facility with Danish biotech SNIPR Biome
SNIPR Biome is a preclinical biotech company developing CRISPR-based therapeutics with the goal of modulating the human microbiome through precision elimination of pathogenic bacteria. The financing will be applied to SNIPR Biome's research and development investments to advance their pipeline of CRISPR-based medicines targeting bacterial infections.
In the context of this financing, SNIPR Biome entered into a phantom share agreement. Plesner played a key role in developing EIB's phantom share framework for use on future venture debt transactions in Denmark. The innovative synthetic warrant structure gives EIB a pre-defined equity stake in SNIPR Biome's development and growth making it more flexible than conventional warrant issuances which are subject to certain strict requirements under Danish corporate law.
Plesner's team on the transaction was Rasmus Mandøe Jensen, Jónas Már Torfason, Lars Bunch, Christian Ellegaard Gejel, and Nathalie Pauline Bramm.